Immunome Statistics

Total Valuation

Immunome has a market cap or net worth of $774.74 million. The enterprise value is $499.16 million.

Market Cap	774.74M
Enterprise Value	499.16M

Important Dates

The next estimated earnings date is Friday, November 15, 2024, before market open.

Earnings Date	Nov 15, 2024
Ex-Dividend Date	n/a

Share Statistics

Immunome has 60.48 million shares outstanding. The number of shares has increased by 242.29% in one year.

Current Share Class	60.48M
Shares Outstanding	60.48M
Shares Change (YoY)	+242.29%
Shares Change (QoQ)	+16.28%
Owned by Insiders (%)	4.25%
Owned by Institutions (%)	69.97%
Float	43.44M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	49.44
Forward PS	n/a
PB Ratio	3.03
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	46.29
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 7.12, with a Debt / Equity ratio of 0.01.

Current Ratio	7.12
Quick Ratio	6.98
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -199.56% and return on invested capital (ROIC) is -34.07%.

Return on Equity (ROE)	-199.56%
Return on Assets (ROA)	-26.85%
Return on Capital (ROIC)	-34.07%
Revenue Per Employee	$196,073
Profits Per Employee	-$4.77M
Employee Count	55
Asset Turnover	0.06
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +44.46% in the last 52 weeks. The beta is 1.82, so Immunome's price volatility has been higher than the market average.

Beta (5Y)	1.82
52-Week Price Change	+44.46%
50-Day Moving Average	13.52
200-Day Moving Average	16.38
Relative Strength Index (RSI)	50.72
Average Volume (20 Days)	524,973

Short Selling Information

The latest short interest is 10.92 million, so 18.06% of the outstanding shares have been sold short.

Short Interest	10.92M
Short Previous Month	12.88M
Short % of Shares Out	18.06%
Short % of Float	25.15%
Short Ratio (days to cover)	12.78

Income Statement

In the last 12 months, Immunome had revenue of $10.78 million and -$262.59 million in losses. Loss per share was -$6.31.

Revenue	10.78M
Gross Profit	-46.96M
Operating Income	-72.53M
Pretax Income	-232.03M
Net Income	-262.59M
EBITDA	-71.56M
EBIT	-72.53M
Loss Per Share	-$6.31

Full Income Statement

Balance Sheet

The company has $278.35 million in cash and $2.77 million in debt, giving a net cash position of $275.58 million or $4.56 per share.

Cash & Cash Equivalents	278.35M
Total Debt	2.77M
Net Cash	275.58M
Net Cash Per Share	$4.56
Equity (Book Value)	253.84M
Book Value Per Share	4.23
Working Capital	244.38M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$60.64 million and capital expenditures -$4.89 million, giving a free cash flow of -$65.53 million.

Operating Cash Flow	-60.64M
Capital Expenditures	-4.89M
Free Cash Flow	-65.53M
FCF Per Share	-$1.08

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-672.53%
Pretax Margin	-2,435.02%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	-361.11%

Dividends & Yields

Immunome does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-242.29%
Shareholder Yield	-242.29%
Earnings Yield	-33.89%
FCF Yield	-8.46%

Analyst Forecast

The average price target for Immunome is $28.75, which is 122.18% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$28.75
Price Target Difference	122.18%
Analyst Consensus	Strong Buy
Analyst Count	4
Revenue Growth Forecast (5Y)	64.88%
EPS Growth Forecast (5Y)	-53.89%

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Immunome has an Altman Z-Score of 6.92 and a Piotroski F-Score of 2.

Altman Z-Score	6.92
Piotroski F-Score	2